Form 8-K - Current report:
SEC Accession No. 0001641172-25-020408
Filing Date
2025-07-21
Accepted
2025-07-21 16:33:11
Documents
13
Period of Report
2025-07-21
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K form8-k.htm   iXBRL 8-K 38733
  Complete submission text file 0001641172-25-020408.txt   248336

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE lixt-20250721.xsd EX-101.SCH 3784
3 XBRL DEFINITION FILE lixt-20250721_def.xml EX-101.DEF 26650
4 XBRL LABEL FILE lixt-20250721_lab.xml EX-101.LAB 36768
5 XBRL PRESENTATION FILE lixt-20250721_pre.xml EX-101.PRE 25274
15 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 5794
Mailing Address 248 ROUTE 25A NO. 2 EAST SETAUKET NY 11733
Business Address 248 ROUTE 25A NO. 2 EAST SETAUKET NY 11733 310 203 2902
LIXTE BIOTECHNOLOGY HOLDINGS, INC. (Filer) CIK: 0001335105 (see all company filings)

EIN.: 202903526 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39717 | Film No.: 251137617
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)